Total Payments
$1.6M
2024 Payments
$320,357
Companies
74
Transactions
1,675
Medicare Patients
413
Medicare Billing
$65,838
Payment Breakdown by Category
Other$983,615 (59.8%)
Consulting$365,141 (22.2%)
Travel$182,852 (11.1%)
Research$78,868 (4.8%)
Food & Beverage$33,895 (2.1%)
Education$299.80 (0.0%)
Gifts$11.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $967,715 | 324 | 58.8% |
| Consulting Fee | $365,141 | 102 | 22.2% |
| Travel and Lodging | $182,852 | 519 | 11.1% |
| Unspecified | $78,868 | 66 | 4.8% |
| Food and Beverage | $33,895 | 645 | 2.1% |
| Honoraria | $15,900 | 7 | 1.0% |
| Education | $299.80 | 8 | 0.0% |
| Gift | $11.96 | 4 | 0.0% |
Payments by Type
General
$1.6M
1,609 transactions
Research
$78,868
66 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $358,246 | 224 | $0 (2024) |
| GENZYME CORPORATION | $246,358 | 184 | $0 (2024) |
| Shire North American Group Inc | $204,776 | 210 | $0 (2019) |
| HEMA Biologics, LLC | $162,352 | 207 | $0 (2024) |
| CSL Behring | $157,113 | 129 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $139,780 | 105 | $0 (2021) |
| Genentech USA, Inc. | $133,408 | 112 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $104,579 | 73 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $42,279 | 48 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $39,697 | 77 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $320,357 | 275 | GENZYME CORPORATION ($88,826) |
| 2023 | $284,710 | 298 | GENZYME CORPORATION ($95,135) |
| 2022 | $191,434 | 235 | Novo Nordisk Inc ($55,439) |
| 2021 | $105,723 | 144 | Novo Nordisk Inc ($30,977) |
| 2020 | $95,409 | 97 | Novo Nordisk Inc ($41,066) |
| 2019 | $229,733 | 221 | Shire North American Group Inc ($83,768) |
| 2018 | $270,237 | 223 | Novo Nordisk Inc ($88,605) |
| 2017 | $147,079 | 182 | Shire North American Group Inc ($60,304) |
All Payment Transactions
1,675 individual payment records from CMS Open Payments — Page 1 of 67
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Immunology | ||||||
| 12/09/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| 12/09/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| 12/09/2024 | Novo Nordisk Inc | Novoeight (Drug), NovoSeven, Rebinyn | Food and Beverage | In-kind items and services | $96.60 | General |
| Category: Hemophilia | ||||||
| 12/08/2024 | Genentech, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $148.68 | General |
| 12/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,118.00 | General |
| 11/25/2024 | Octapharma USA, Inc. | WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $55.68 | General |
| Category: COAGULATION | ||||||
| 11/24/2024 | Novo Nordisk Inc | Esperoct (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,991.25 | General |
| Category: Hemophilia | ||||||
| 11/24/2024 | Novo Nordisk Inc | Esperoct (Biological) | Travel and Lodging | In-kind items and services | $1,203.52 | General |
| Category: Hemophilia | ||||||
| 11/24/2024 | Novo Nordisk Inc | Esperoct (Biological) | Travel and Lodging | In-kind items and services | $846.22 | General |
| Category: Hemophilia | ||||||
| 11/24/2024 | Novo Nordisk Inc | Esperoct (Biological) | Travel and Lodging | In-kind items and services | $186.61 | General |
| Category: Hemophilia | ||||||
| 11/24/2024 | Novo Nordisk Inc | Esperoct (Biological) | Food and Beverage | In-kind items and services | $66.34 | General |
| Category: Hemophilia | ||||||
| 11/21/2024 | CSL Behring | HEMGENIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,760.00 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $61,453 | 44 |
| A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A | GENZYME CORPORATION | $6,500 | 1 |
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV00 | BIOVERATIV THERAPEUTICS INC. | $2,002 | 5 |
| Emicizumab Minor Surgery | F. Hoffmann-La Roche AG | $1,957 | 2 |
| Clinical Characteristics and Outcomes of Hemophilia B Patients Managed with ALPROLIX in Routine Clinical Practice | BIOVERATIV THERAPEUTICS INC. | $1,795 | 1 |
| A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients >=12 Years of Age With Severe Hemophilia A | GENZYME CORPORATION | $1,250 | 3 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A | GENZYME CORPORATION | $1,000 | 3 |
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A Phase 1, Single-Site, Open-Label Study to Assess Pharmacokinetics of Efanesoctocog Alfa (BIVV001), Standard Half-Life and Extended Half-Life FVIII After Each Single Intravenous Injection in a Fixed Sequence, in Previously Treated Adults With Severe Hemophilia A | GENZYME CORPORATION | $750.00 | 2 |
| An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A | GENZYME CORPORATION | $750.00 | 2 |
| BIVV001: The First Investigational Factor VIII (FVIII) Therapy to Break Through the Von Willebrand Factor (VWF) Ceiling, with Potential for More Optimal, Extended Protection in Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $265.00 | 1 |
| BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $205.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 105 | 216 | $55,817 | $15,517 |
| 2022 | 2 | 46 | 79 | $27,305 | $6,846 |
| 2021 | 2 | 42 | 116 | $37,150 | $10,583 |
| 2020 | 8 | 220 | 647 | $121,333 | $32,892 |
Total Patients
413
Total Services
1,058
Medicare Billing
$65,838
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 83 | $32,520 | $9,070 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 72 | $19,210 | $5,234 | 27.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 22 | 61 | $4,087 | $1,214 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 48 | $18,897 | $4,757 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 31 | $8,408 | $2,089 | 24.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 63 | $23,688 | $6,765 | 28.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 53 | $13,462 | $3,819 | 28.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 74 | 197 | $67,390 | $18,092 | 26.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 66 | 198 | $46,132 | $12,723 | 27.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 14 | 18 | $2,530 | $734.26 | 29.0% |
| 96361 | Hydration infusion into a vein | Office | 2020 | 11 | 41 | $1,929 | $504.79 | 26.2% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 15 | 20 | $1,430 | $403.70 | 28.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 15 | 51 | $1,395 | $393.55 | 28.2% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2020 | 13 | 30 | $219.32 | $30.65 | 14.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 12 | 92 | $308.00 | $8.93 | 2.9% |
About Dr. Doris Quon, M.D
Dr. Doris Quon, M.D is a Hematology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578589271.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Doris Quon, M.D has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $320,357 received in 2024. These payments were reported across 1,675 transactions from 74 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($967,715).
As a Medicare-enrolled provider, Quon has provided services to 413 Medicare beneficiaries, totaling 1,058 services with total Medicare billing of $65,838. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Los Angeles, CA
- Active Since 07/14/2006
- Last Updated 10/10/2013
- Taxonomy Code 207RH0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578589271
Products in Payments
- ADVATE (Biological) $175,241
- SevenFact (Biological) $161,422
- HEMGENIX (Biological) $146,885
- ALTUVIIIO (Biological) $113,338
- HEMLIBRA (Biological) $89,513
- ELOCTATE (Drug) $80,159
- NovoSeven RT (Drug) $66,660
- Esperoct (Biological) $49,483
- ELOCTATE (Biological) $31,607
- ALPROLIX (Biological) $26,498
- REBINYN (Biological) $26,327
- Rebinyn (Biological) $25,767
- Novoeight (Drug) $21,434
- Jivi (Drug) $21,121
- Eloctate (Drug) $19,935
- NO PRODUCT DISCUSSED (Drug) $14,810
- REBINYN (Drug) $13,816
- VONVENDI (Biological) $13,241
- ADYNOVATE (Biological) $11,800
- Alprolix (Drug) $10,152
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Los Angeles
Dr. Ilene Weitz, M.d, M.D
Hematology — Payments: $857,023
Hematology $857,023
Dr. Syma Iqbal, M.d, M.D
Hematology — Payments: $172,602
Hematology $172,602
Robert Chen, Md, MD
Hematology — Payments: $117,792
Hematology $117,792
Dr. Ann Mohrbacher, M.d, M.D
Hematology — Payments: $78,192
Hematology $78,192
Dr. Endi Wang, M.d, M.D
Hematology — Payments: $14,310
Hematology $14,310
Navid Hafez, M.d, M.D
Hematology — Payments: $11,391
Hematology $11,391